FIBROLAMELLAR CARCINOMA
Clinical trials for FIBROLAMELLAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR CARCINOMA trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail offers hope for kids with rare cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with relapsed or hard-to-treat solid tumors. The goal is to find safe doses and see if the treatment shrinks tumors. The trial has two parts: fir…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 07:01 UTC
-
Immunotherapy drug shows promise for tough childhood liver cancers
Disease control Recruiting nowThis study tests whether the immunotherapy drug pembrolizumab (Keytruda) can help children and young adults with a rare liver cancer that has returned or not responded to standard treatment. About 18 participants will receive the drug, and researchers will measure how well it shr…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE2 • Sponsor: Allison O'Neill, MD • Aim: Disease control
Last updated May 26, 2026 07:00 UTC
-
New hope for rare cancers: immunotherapy trial targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 18, 2026 12:13 UTC